Navigation Links
MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
Date:12/13/2007

rint(R) is a powerful predictor of disease outcome in lymph node positive breast cancer patients," said Prof. Dr. Rene Bernards, chief scientific officer at Agendia. "Based on these data, the inclusion criteria of the large MINDACT clinical trial using MammaPrint(R) will be enlarged to include patients with 1-3 positive nodes."

Agendia will start offering MammaPrint(R) to patients having 1-3 positive lymph nodes in Europe. These data will also be submitted to the U.S. Food and Drug Administration (FDA) for regulatory approval at a later date.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA approval for its breast cancer test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type
'/>"/>

SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Expands Decision Resources, Inc.,s Portfolio to Include Global ... Physician and Consumer Digital Market Research, ... Inc., one of the world,s leading research and advisory ... it,acquired Manhattan Research, a leading provider of access to ...
... AVIV, Israel, June 17 BSP Ltd.,( http://www.bsp.co.il/pressall.asp ... for non-invasive diagnosis and monitoring of Ischemic Heart,Disease, ... a private,funding round, that included existing shareholders in ... developed the HyperQ(TM), a cutting-edge technology that offers,highly ...
... and fast PCR amplification ... in a fully portable ... a leading,developer of state-of-the-art PCR devices and Cell-based assay systems,today ... San,Diego Convention Center that it has successfully completed development of,Palm ...
Cached Biology Technology:Decision Resources, Inc. Acquires Manhattan Research 2Decision Resources, Inc. Acquires Manhattan Research 3BSP Raises $2.6 Million Dollars From Private Investors 2Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device 2
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2
... As the 2010 United Nations International Year of ... (MBG) and the Royal Botanic Gardens, Kew (RBG Kew) ... international resource is a working list of all land ... diversity and effective conservation of plants. The completion of ...
... In a recent issue of HortTechnology , Purdue ... on a study of the effects of a technique called ... are commonly applied as sprays or media drenches, bulb crops ... The experiments were designed to determine if dipping Easter lily ...
... Dec. 29, 2010 Patients with diabetes, kidney disease and ... have a higher risk of cardiovascular disease or death, researchers ... results suggest that testing such patients, responsiveness to the drug ... their risk, said Dr. Robert Toto, professor of internal medicine ...
Cached Biology News:Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 2Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 3Bulb dipping controls Easter lily growth 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 3
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: